In a randomized, double-blind, placebo controlled crossover study, 19 volunteers consumed 3 doses of resVida (30 mg, 90 mg, 270 mg) and a placebo at weekly intervals. Flow-mediated dilatation (FMD) of the brachial artery was measured one hour after ingestion of each treatment and was significantly increased at all 3 doses relative to placebo. 30 mg of resVida demonstrated 2.5% greater increase in FMD relative to placebo.
SpecificationsIn order to provide a more relevant experience for you, we use cookies to enable some website functionality. Some of the cookies are used for statistical purposes while others are set up by third party services.
By clicking "Allow", you accept the use of all the cookies on the platform. Click "Decline Non Essential" to select only strictly necessary, or "Preferences" to make more detailed choices.